866-997-4948(US-Canada Toll Free)

U.S Market Study on Polycystic Ovarian Syndrome Treatment: Insulin Sensitizing Agents Drug Class Segment Projected to Reflect Highest Market Attractiveness Index Through 2024

Published By :

Persistence Market Research

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 70 Pages

The polycystic ovarian syndrome treatment market in the U.S is highly competitive due to the presence of many local manufacturers and prevalence of low-cost generic drugs. However, manufacturers of brands in the country have strategically maintained their position in the market, owing to the unique value proposition and comparatively lesser side effects. The analysts of Persistence Market Research, while drafting a report on the U.S. polycystic ovarian syndrome treatment market titled Polycystic Ovarian Syndrome Treatment Market: U.S. Industry Analysis and Forecast, 20162024, have observed that alliances with e-commerce partners and distribution agreements with strong local players is the key market strategy that is being followed by leading players in this market. While concentrating on target geographies, the analysts have further observed that the U.S. is a highly mature market where manufacturers are focused on developing advanced direct first line therapeutics for the treatment of polycystic ovarian syndrome with fewer side effects. Similarly, companies are also entering into strategic agreements with distributors and local players to increase the availability of their products in order to expand their market footprint.

After a detailed study of the U.S. polycystic ovarian syndrome treatment market, the analysts have found that the U.S. shows a high prevalence rate of polycystic ovarian syndrome. This syndrome is associated with several other conditions such as type 2 diabetes mellitus, obesity, hirsutism and others. Also, women with polycystic ovarian syndrome are at a greater risk of developing type 2 diabetes mellitus. According to the report, the U.S. polycystic ovarian syndrome treatment market comprises several pharmaceutical drugs manufacturers based in the U.S. However, due to lack of FDA approved drugs for PCOS treatment, the market is dominated by small generic drugs manufacturers. These companies follow strong marketing and distribution strategies for facilitating a higher adoption of their polycystic ovarian syndrome treatment drugs across the country.

Persistence Market Research provides key strategic recommendations for existing and new players in the market

The U.S. polycystic ovarian syndrome treatment market report begins with an overview of the entire market. The report also underlines factors influencing the growth of the U.S. polycystic ovarian syndrome treatment market along with a detailing of the key trends, drivers, restraints, opportunities for market players and regulations. Impact analysis of key growth drivers and restraints based on the weighted average model along with important trends is included in the report to better equip clients with information and hidden insights. At the end of the report, Persistence Market Research provides key strategic recommendations for both existing and new players in the market to emerge sustainably profitable. A detailed analysis has been provided for each market segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractiveness index and BPS analysis.

The next few sections provide a detailed analysis of every segment and sub-segment of the U.S. polycystic ovarian syndrome treatment market. The report further highlights the growth trends of the polycystic ovarian syndrome treatment market across the U.S and presents a market outlook for 20162024 showcasing key trends contributing to the growth of the polycystic ovarian syndrome treatment market in the U.S. as well as an analysis of the extent to which drivers are influencing this market. The final section of the report includes detailed company profiles with company-specific long-term and short-term strategies, key offerings, and recent developments in the U.S polycystic ovarian syndrome treatment market.

Market Segmentation

By Drug Class

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Anti-Depressants
  • Ornithine
  • Decarboxylase Inhibitors
  • Aromatase Inhibitors and SERMs
  • Diuretics

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores / OTC
  • e-Commerce
  • Fertility Clinics

Research Methodology

The report considers 2015 as the base year and provides data for the forecast period 20162024. To deduce market size, the report considers various viewpoints based on extensive primary and secondary research. The report begins by sizing the current market a key indicator of how the market is likely to grow during the forecast period. Given the characteristics of the market, the report presents triangulated data on the basis of supply side and demand side analysis and other dynamics of the U.S polycystic ovarian syndrome treatment market. Indicators such as the number of polycystic ovarian syndrome patients per year, diagnosis rate, treatment rate, etc., have been considered to arrive at the indicated market numbers. Similarly, historical trends pertaining to the demand for drugs among polycystic ovarian syndrome patients have been analyzed to track data. Yearly change in inflation rate has not been factored while forecasting market numbers. Bottom-up approach has been used to assess market numbers for each product category, while top-down approach has been used to counter-validate the reached numbers.

Company Profiles 

  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Merck KGaA
  • AstraZeneca
  • Others

1.Executive Summary

2.Market Introduction

2.1.Market Definition
2.2.Market Taxonomy

3.Market Analysis Scenario
3.1.Market Size (US$ Mn) and Forecast
3.1.1.Market Size and Y-o-Y Growth
3.1.2.Absolute $ Opportunity
3.2. Market Overview
3.2.1.Value Chain

4.Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1.Supply Side
4.2.2.Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Forecast Factors Relevance and Impact
4.6. Disease Epidemiology (2015)
4.7. Prescription and Average Duration of Treatment
4.8. Case Study

5.U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Drug Class
5.1. Introduction
5.1.1.Basis Point Share (BPS) Analysis By Drug Class
5.1.2.Y-o-Y Growth Projections By Drug Class
5.2. Market Size (US$ Mn) and Forecast By Drug Class
5.2.1. Contraceptives
5.2.2. Insulin Sensitizing Agents
5.2.3. Anti-Depressants
5.2.4. Ornithine Decarboxylase Inhibitors
5.2.5. Aromatase Inhibitors & SERMs
5.2.6. Diuretics Market Attractiveness Analysis By Drug Class
5.3.U.S. Polycystic Ovary Syndrome Treatment Market Attractiveness Analysis By Drug Class

6.U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Distribution Channel
6.1. Introduction
6.1.1.Basis Point Share (BPS) Analysis By Distribution Channel
6.1.2.Y-o-Y Growth Projections By Distribution Channel
6.2.Market Size (US$ Mn) Forecast By Distribution Channel
6.2.1. Hospitals Pharmacies
6.2.2. Drugs Store/OTC
6.2.3. E-Commerce
6.2.4. Fertility Clinics
6.3.U.S. Polycystic Ovary Syndrome Treatment Market Attractiveness Analysis, By Distribution Channel

7.Competition Landscape
7.1. Company Profiles (Details Overview, Financials, Strategy, Recent Developments)
7.2. Key Players
7.2.1. Revenue
7.2.2. Company Highlights
7.2.3. Key Players
7.2.3.1. Sanofi
7.2.3.2. Novartis AG
7.2.3.3.Teva Pharmaceutical Industries Limited
7.2.3.4.Merck KGaA
7.2.3.5.AstraZeneca

8. Assumptions and Acronyms Used

9. Research Methodology

List of Table

Table 01: U.S. Polycystic Ovary Syndrome Drugs Market Value Analysis, by Drug Class, 20152024 (US$ Mn)
Table 02: U.S. Polycystic Ovary Syndrome Drugs Value Analysis, by Distribution Channel, 20152024 (US$ Mn)

List of Chart

Figure 1. U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Drug Class, 2016
Figure 2. U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Distribution Channel, 2016
Figure 3: U.S. Polycystic Ovary Syndrome Drugs Market Value, US$ Mn, 20152024
Figure 4: U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Drug Class Type (%), 20162024
Figure 5: U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Drug Class, 20162024
Figure 6: U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Drug Class, 20162024
Figure 7: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Contraceptives, 2016 2024
Figure 8: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Contraceptives Segment, 2016 2024 (US$ Mn
Figure 9: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Insulin Sensitizing Agents, 2016 2024
Figure 10: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Insulin Sensitizing Agents Segment, 2016 2024 (US$ Mn)
Figure 11: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Anti-Depressants, 2016 2024
Figure 12: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Anti-Depressants Segment, 2016 2024 (US$ Mn)
Figure 13: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Ornithine Decarboxylase Inhibitors, 2016 2024
Figure 14: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Ornithine Decarboxylase Inhibitors Segment, 2016 2024 (US$ Mn)
Figure 15: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Aromatase Inhibitors & SERMs, 2016 2024
Figure 16: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Aromatase Inhibitors & SERMs Segment, 2016 2024 (US$ Mn)
Figure 17: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Diuretics, 2016 2024
Figure 18: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Diuretics Segment, 2016 2024 (US$ Mn)
Figure 19: U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Distribution Channel (%), 2016 & 2024
Figure 20: U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Distribution Channel, 20162024
Figure 21: U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Distribution Channel, 20162024
Figure 22: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016 2024
Figure 23: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Hospital Pharmacies, 2016 2024 (US$ Mn)
Figure 24: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores/OTC, 2016 2024
Figure 25: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Drug Stores/OTC, 2016 2024 (US$ Mn)
Figure 26: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016 2024
Figure 27: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by E-commerce, 2016 2024 (US$ Mn)
Figure 28: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Fertility Clinics, 2016 2024
Figure 29: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Fertility Clinics, 2016 2024 (US$ Mn)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *